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Three papers recently published in Nature Medicine provide the most detailed analyses of fetal midbrain
grafts in patients with Parkinson’s disease. Some of the results are surprising and suggest a new wave of
questions aimed at both the value of cell therapy and the nature of the disease itself.For a long time,.transplanta-
tion.was frowned upon.. So
deep-seated, however, and of such
long standing is the human prefer-
ence for being alive that these
spokesmen have not carried their
point.
—P.B. Medawar and J.S. Meda-
war, Aristotle to Zoos, Harvard Uni-
versity Press, 1983
Approximately one million, mostly el-
derly, Americans suffer from Parkinson’s
disease (PD), and asmany as three million
more have yet to be diagnosed. PD
causes the degeneration of the midbrain
dopamine neurons controlling movement
and gait. Although themovement disorder
is an obvious outward sign, the disease
involves a more widespread dysfunction
and degeneration. Many of the motor
symptoms can be treated for several
years with L-DOPA, which is readily
converted to dopamine by the remaining
dopamine neurons. Eventually, nearly all
of the dopamine neurons succumb to
the degenerative process, and patients
become unresponsive to L-DOPA. Be-
cause of the important role of dopamine
neurons, there has been extensive inter-
est in the idea that diseased cells might
be replaced by transplantation.
Cell therapies for PD currently use fetal
midbrain precursors, and, because ac-
cess to fetal tissue is limited, pluripotent
stem cells are seen as a source of dopa-
mine neurons in the future. The first
transplants of fetal midbrain tissue into
Parkinson’s disease patients were per-
formed almost 2 decades ago. These sur-
geries appear to cause an improvement
in motor function, lasting several years.However, more recent clinical trials failed
to support the original interpretation, rais-
ing doubts about the merit of cell therapy
in the clinical setting. Three recent papers
analyze the brains of eight PD patients
who received grafts of human fetal mid-
brain tissue 9–16 years earlier (Kordower
et al., 2008; Li et al., 2008; Mendez
et al., 2008). The grafts show concerning
features, including the inappropriate pres-
ence of serotonin neurons, low levels of
the plasma membrane transporter that
regulates dopamine function, and the
presence of Lewy bodies that are thought
to mark diseased tissue.
Specifically, in two of the studies, Lewy
bodies are found within the graft. Kor-
dower et al. describe a woman who re-
ceived bilateral transplants after suffering
with PD for 22 years. Although transplan-
tation remedied the disease, she began to
re-experience motor problems 11 years
later. She died of cardiac arrest, presum-
ably unrelated to PD, 14 years after
transplantation and 3 years after her par-
kinsonian symptoms resurfaced. Li et al.
describe two individuals who received
two separate transplants, one to each
hemisphere. These patients died 16/12
(left side/right side) and 13/11 (left side/
right side) years after transplantation. All
three of these patients in the studies of
Kordower et al. and Li et al. developed
Lewy bodies within the grafted tissue.
In contrast, Mendez et al. performed
postmortem analysis on the brains of
five patients who had been transplanted
between 9 and 14 years earlier. Unlike
Kordower et al. and Li et al., Mendez
et al. were unable to find any Lewy body
pathology within the grafts in these pa-
tients. All together, three out of eightNeuronbrains transplanted for 9+ years con-
tained Lewy bodies within the grafts.
While the number of brains analyzed is
small, these studies suggest that the de-
velopment of Lewy body pathology is
not uncommon in fetal midbrain grafts.
Still, these results also suggest that fetal
midbrain grafts can remain unaffected
by Lewy bodies for a decade or more,
which would be meaningful, particularly
for L-DOPA-unresponsive patients. It is
clear that the transplantation of dopamine
neurons into human beings has not yet
been optimized.
The uncertain clinical prospects for cell
therapy contrast with scientific and politi-
cal forces that are generating a wide inter-
est in dopamine neurons. On the scientific
side of this dialectic, there is increasing
information about the origin of dopamine
neurons in normal mammalian develop-
ment and in the virtual development
made possible by pluripotent stem cell
technologies. Funding institutions around
the world are supporting a major invest-
ment based on this technology, but the
same issue of Nature Medicine that re-
ports the graft pathology also contains
a strong attack on the premise that cell
transplantation is a suitable approach to
PD (Braak and Del Tredici, 2008). The
most significant finding, observed in two
of the papers, is the identification of ubiq-
uitin and a-synuclein-immunoreactive
subcellular aggregates that resemble
Lewy bodies (Li et al., 2008; Kordower
et al., 2008). In their commentary, Braak
and Del Tredici argue that the disease pa-
thology in the grafts strengthens the view
that cell therapies in PD are not likely to
work. Their main point is that transplanta-
tion does not address the root cause of58, June 12, 2008 ª2008 Elsevier Inc. 659
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only affects dopamine neurons when
widespread damage in other regions is
already underway.
Lewy bodies are protein aggregates
found in some but not all patients with
Parkinson’s disease andwith other neuro-
degenerative disease. Lewy bodies con-
tain a-synuclein, neurofilament, crystallin,
and proteins of the proteasome. a-synu-
clein holds a special place in our under-
standing of PD because mutations in this
gene provided the first example of a ge-
netic cause of PD. a-synuclein is associ-
ated with synaptic vesicles in wide re-
gions of the brain, and mice expressing
mutant a-synuclein develop Lewy bodies.
a-synuclein pathologies are also associ-
ated with other brain diseases in a com-
plex manner. Even within a single kindred,
a-synuclein mutation can cause a parkin-
sonian outcome alongside very different
brain diseases (Singleton et al., 2003). In
PD patients, Lewy bodies are commonly
found in midbrain dopamine neurons
and, importantly, in other neurons. Lewy
body pathology is used to define the pro-
gression of PD and suggests that other
cells are affected before dopamine neu-
rons (see Braak and Del Tredici, 2008). It
follows that the disease is not a cell-au-
tonomous problem in dopamine neurons
and that therapies are needed that
address damage to other brain regions.
The idea that neurodegeneration is not
a simple cell-autonomous problem is
supported by studies of other diseases.
Amyotrophic lateral sclerosis (ALS) is
characterized byaprogressive loss ofmo-
tor neurons, and a small percentage of
ALS cases are associated with mutations
in the superoxide dismutase 1 (SOD1)
gene. Transgenic andmutantmicemisex-
pressing disease-causing SOD1 proteins
show motor neuron degeneration and
motor difficulties seen in ALS. When the
mutant SOD1 specifically is expressed in
motor neurons, they degenerate. More
surprising is the observation that reducing
the expression of mutant SOD1 in astro-
cytes slows the progression of motor neu-
ron degeneration. Consistent with this
finding, in vitro experiments show that
glia expressing mutant SOD1 induce cell
death in cocultured ES cell-derived motor
neurons, regardless of the genotype of the
motor neurons. A recent studywith chime-
ric mice suggests that ALS is initiated by660 Neuron 58, June 12, 2008 ª2008 Elseviemutant SOD1 expressed in cells other
than motor neurons (Yamanaka et al.,
2008; this reference includes citations to
many of the other observations discussed
here). Studies with mouse mutants and
bone marrow transplantation suggest an
involvement of microglia in motor neuron
degeneration. A role for microglia in
SOD1-induced motor neuron loss is sup-
ported by fractalkine receptor mutants.
Fractalkine is a chemokine (CX3CL1) that
protects motor neurons from the damag-
ing effects of the SOD1G93A mutation by
inhibiting inflammatory responses (Car-
dona et al., 2006). The loss of neurotrophic
factors generated by the vascular system
has also been suggested as a cause for
ALS. The conditional deletion of vascular
endothelial growth factor (VEGF) leads to
the degeneration of motor neurons, and
genetic variants in the VEGF and angioge-
nin, another related factor that regulates
endothelial cells, are associated with the
development of ALS (Greenway et al.,
2006). These results suggest that inter-
actions between cells of the immune,
vascular, and nervous systems regulate
initiation and progression of ALS.
Huntington’s disease (HD) is an autoso-
mal-dominant disease where loss of
striatal neurons is a major feature of the
symptoms. The protein mutated in HD,
huntingtin, has been shown to regulate
levels of the neurotrophic factor BDNF,
and cortical levels of BDNF protein are
low in the brains of HD patients. BDNF ex-
pressed in layer V/VI cortical pyramidal
neurons is delivered to the striatum by an-
terograde transport, but the deficit in HD
may start in a cortical interneuron (Gu
et al., 2005). Like HD, the spinocerebellar
ataxias (SCA) are caused by mutations
that result from polyglutamine (polyQ)
expansion. There are six forms of SCA
caused by polyQ expansion in different
proteins. When the repeat lengths are
low, the diseases appear distinct, but
the pathologies overlap with increasing
copies of the triplet repeat (Orr and
Zoghbi, 2007). SCA1 is caused by muta-
tion in ataxin 1 that leads to degeneration
of Purkinje cells. Remarkably, studies in
mice show that the toxicity results from
‘‘hit-and-run’’ expression of the mutant
during Purkinje cell development (Orr
and Zoghbi, 2007). As these experiments
show, understanding cell interactions in
space and time will play an importantr Inc.role in our understanding of polyQ-depen-
dent neuron loss.
With these data in mind, let’s return to
PD. Although little is known about the
mechanisms responsible for the initiation
of PD, mutations have been identified
that are thought to cause Parkinson’s dis-
ease in a small number of cases. The
identification of PARK genes, including
a-synuclein, has provided many new in-
sights into disease progression. However,
PARK gene expression is not limited to
dopamine neurons and, as Braak and
Del Tredici stress, other cells show pa-
thology at early stages of PD. In addition
to the involvement of other neurons, there
is strong evidence for ongoing immune
system involvement in the substantia ni-
gra of PD patients and in disease models
(McGeer and McGeer, 2004). A remark-
able accident where individuals were
briefly exposed to the toxin MPTP shows
a long-lasting sensitivity of dopamine
neurons (Langston et al. 1999). These re-
sults suggest that a transient insult may
trigger a diseased state involving multiple
cell types in the midbrain that also dis-
rupts other brain regions.
The case reports and the welcome
frank tone of the commentary on grafted
PD patients encourage stem cell re-
searchers to attend to the distributed pa-
thology of this devastating illness. It would
be hard to justify the current interest in de-
riving dopamine neurons from stem cells
to treat a disease triggered and sustained
by ongoing pathology in other cell types.
However, there are two good reasons to
believe that interest in the production of
dopamine neurons from stem cells will
not diminish but grow. The first is the clear
evidence that stem cell-derived dopa-
mine neurons function in vivo (Kim et al.,
2002). The use of stem cell-derived neu-
rons in the clinic will require amore careful
assessment of their properties. However,
the production of dopamine neurons in the
laboratory is not simply a logistical sup-
port for cell therapy. Dopamine neurons
are of great interest in human behavior
and psychiatry, ensuring a high interest
in their synthesis from stem cells.
The second argument for continued in-
terest in the ex vivo production of these
cells is the unexpected finding that the
mechanisms controlling the birth and
death of adult dopamine neurons may
be linked. Dopamine neurons are
Neuron
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floor-plate. The floor-plate is specified
by the transcription factor foxa2, and
overexpression of foxa2 in ES cells
boosts the production of dopamine neu-
rons. In the adult brain, the transcription
factor foxa2 is largely restricted to dopa-
mine neurons, where it is central to their
survival in old age (Kittappa et al., 2007).
Remarkably, the spontaneous degenera-
tion of dopamine neurons in foxa2+/
mice is similar to the dopamine neuron
loss seen in PD patients, suggesting
sensitive new assays tomonitor early dys-
function. This animal model for spontane-
ous dopamine neuron loss in old age may
provide new ways of probing the place of
these cells in the hierarchy of disease
progression and a new understanding of
endogenous stressors. The relevance of
these findings to PD may be assessed in
neurons derived from pluripotent human
cells.
Although these new insights into the
birth and death of dopamine neurons
are significant, the reports in Nature
Medicine stress the value of tools that
routinely monitor and manipulate the
many other cell types showing diseasepathology. Transplanting dopamine neu-
rons, whether they are derived from the
fetal brain or generated in the laboratory,
seems an unlikely strategy to achieve
a widespread effect. Of course, partial
benefit would be acceptable, but simple
strategies that reach all the affected cells
might move us closer to addressing
the distributed pathology seen in many
degenerative disorders. Progress toward
this goal would justify the world-wide
interest in the stem cell field.
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